Myriad Genetics Inc (MYGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $542.92M
Last updated: Nov 17, 2026 at 11:06 AM ET
Myriad Genetics Inc (MYGN) Valuation Multiples
Myriad Genetics (MYGN) trades at 0.7x sales and 2.0x book value. Its P/S of 0.7x is below its 5-year median of 2.1x. Its forward P/E is 54.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 54.0x |
| Price to sales | 0.7x |
| Price to book | 2.0x |
| PEG | N/A |
| FCF yield | -6.4% |
Historical Medians
Against its 10-year medians, its P/S is 70.8% below 2.4x and its P/B is in line.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 0.7x | 2.1x | 2.4x |
| P/B | 2.0x | 1.9x | 2.0x |
Valuation History
Over the 5 of the 10 year ends shown that have a P/E, its P/E ranged from 13.7x in 2016 to 105.5x in 2024. 2024 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $6.15 | N/A | 0.7x | 1.6x |
| 2024 | $13.71 | 105.5x | 1.5x | 1.8x |
| 2023 | $19.14 | N/A | 2.1x | 2.1x |
| 2022 | $14.51 | N/A | 1.7x | 1.3x |
| 2021 | $27.60 | N/A | 3.1x | 2.3x |
| 2020 | $19.78 | N/A | 2.8x | 1.7x |
| 2019 | $27.23 | 23.1x | 2.8x | 1.9x |
| 2018 | $29.07 | 19.4x | 2.6x | 2.0x |
| 2017 | $34.35 | 30.1x | 3.3x | 2.6x |
| 2016 | $16.67 | 13.7x | 1.6x | 1.6x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MYGN
What is MYGN's forward P/E ratio?
Myriad Genetics has a forward P/E ratio of 54.0x.
Is MYGN stock overvalued?
GNG's valuation label for MYGN is Undervalued.
What is MYGN's price to sales ratio?
Myriad Genetics has a price to sales ratio of 0.7x.
MYGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts